The people building the earliest possible warning.
Molecular biology, patient data, and machine learning under one roof — guided by a clinical and scientific advisory board in kidney cancer, nephrology, oncology, and cancer genomics.
The founding team.
-
Muhammed Sadık Yıldız, PhD
Co-Founder & CEO
PhD in systems biology, Harvard. Built the discovery pipeline and the lead classifier; leads data infrastructure and CLIA assay translation.
-
Erdal Toprak, PhD
Co-Founder & Chief Scientific Officer
Professor at UT Southwestern. His lab developed the whole-blood RNA platform; directs the scientific program and assay development.
-
Muhammed Ali Yıldırım, PhD
Chief Strategy Officer
Director of Academic Research at Harvard’s Growth Lab and Brown University’s Global Linkages Lab. Leads growth and long-horizon planning.
-
Yaming Xue, MD
Scientific Advisor
Blood-processing specialist at UT Southwestern. Two decades of experience processing human blood for sequencing-based assays.
Clinical and scientific counsel.
-
Sarah Huen, MD, PhD
Physician-scientist in nephrology and kidney metabolism, UT Southwestern. Guides renal host-response biology and clinical study design.
-
David Gerber, MD
Leads lung-cancer clinical trials at UT Southwestern; shaped modern trial-eligibility standards. Advises clinical validation, trial design, and the regulatory path.
-
Mazhar Adli, PhD
Tumor genomics and functional cancer genetics, Northwestern University. Advises biomarker mechanism and target validation.